Beryl Drugs Ratios

Beryl Drugs Ltd Ratios

The Beryl Drugs Ltd Ratios page provides a complete fundamental analysis of Beryl Drugs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Beryl Drugs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Beryl Drugs Ltd (NSE: , BSE: 524606) is currently trading at ₹20.19, with a market capitalization of ₹102.4M. As a major player in the Health technology sector and Pharmaceuticals: other industry, Beryl Drugs Ltd remains a key stock for fundamental analysis using Beryl Drugs Ltd Ratios.

Beryl Drugs Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Beryl Drugs Ltd P/E ratio currently stands at 18.45, making it one of the most tracked metrics in Beryl Drugs Ltd Ratios.

Historically, the Beryl Drugs Ltd P/E ratio has shown strong fluctuations:

• 2024: 18.45
• 2023: 19.35
• 2022: 8.05
• 2021: 0
• 2020: 13.99

The decline in Beryl Drugs Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Beryl Drugs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.12.

Historical P/B trend:

• 2024: 1.12
• 2023: 1.67
• 2022: 0.76
• 2021: 0.73

Beryl Drugs Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Beryl Drugs Ltd P/S ratio currently stands at 0.51, an important part of Beryl Drugs Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.51
• 2023: 0.56
• 2022: 0.23
• 2021: 0.37

A stable or declining Beryl Drugs Ltd P/S ratio indicates cautious market sentiment.

Beryl Drugs Ltd Price to Cash Flow Ratio (P/CF)

The Beryl Drugs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 5.07.

Historical Beryl Drugs Ltd Price to Cash Flow Ratio:

• 2024: 5.07
• 2023: 41.70
• 2022: 3.15
• 2021: 0
• 2020: 0

The declining Beryl Drugs Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Beryl Drugs Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Beryl Drugs Ltd EV currently stands at ₹138.68M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 138.68M
• 2023: 197.46M
• 2022: 101.35M
• 2021: 99.22M

Beryl Drugs Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Beryl Drugs Ltd EV/EBITDA ratio is currently 11.25, a key metric in Beryl Drugs Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 11.25
• 2023: 8.65
• 2022: 5.16
• 2021: 23.83

Higher Beryl Drugs Ltd EV/EBITDA suggests premium valuation.

Beryl Drugs Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Beryl Drugs Ltd D/E ratio is currently 0.43, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.43
• 2023: 0.57
• 2022: 0.56
• 2021: 0.73

Beryl Drugs Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Beryl Drugs Ltd ROE currently stands at 6.28%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 6.28
• 2023: 9.05
• 2022: 9.97
• 2021: -8.66

Declining ROE indicates pressure on profitability.

Beryl Drugs Ltd Ratios Analysis Summary

The Beryl Drugs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Beryl Drugs Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Beryl Drugs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.